BIOBRIEF
The clinical stage South Korean RNA therapy developer is the latest tenant at Lilly Gateway Labs, a co working accelerator for early stage biotechs inside Eli Lilly's broader external R&D network, alongside Haya Therapeutics, Circular Genomics, and
Rznomics, a clinical-stage South Korean developer of RNA-based gene therapies, has taken a seat at Lilly Gateway Labs in San Diego, Eli Lilly's newest accelerator site.
The biotech joins Haya Therapeutics and Circular Genomics in the San Diego building, with Kenai Therapeutics also running research space there per Genetic Engineering News. Lilly has separately announced a Philadelphia LGL site, signaling the Gateway Labs model is expanding beyond California.
Rznomics says the seat will be used to push candidate discovery through a self-described database of more than 200 disease targets, recruit US R&D staff, and build clinical infrastructure for its lead programs. CEO Seong-Wook Lee, quoted by Genetic Engineering News, called the move a milestone for the company's RNA platform.
Gateway Labs sits inside Lilly's Catalyze360 network, a bundle that includes Lilly Ventures, ExploR&D, and TuneLab, Lilly's external-innovation package for early-stage biotech partners. No deal terms, named candidates, or seat length have been disclosed, and the "200-plus targets" figure is Rznomics' own framing.